There is a new shot hitting bariatric-surgery weight loss numbers without the surgery. In the phase 3 TRIUMPH-1 trial, the highest dose produced an average of 28.3 percent body weight loss at 80 weeks. That is almost twice the weight loss we saw in semaglutide's pivotal obesity trial.

I am a nephrologist and an obesity medicine specialist, and I have been waiting on this data for two years. The phase 3 numbers finally dropped, and they are not subtle. Below, I walk through exactly how this drug, retatrutide, works, the side effect that matters most for your kidneys, the realistic timeline to get it, and why the compounded retatrutide being sold online is not the drug that was studied.

The TRIUMPH-1 data

On May 21, 2026, Eli Lilly announced topline results from TRIUMPH-1, a phase 3 obesity trial of 2,339 adults with obesity or overweight and at least one weight-related condition, without diabetes. At 80 weeks, the 12 mg dose produced an average weight loss of 70.3 pounds. That works out to 28.3 percent of body weight.

Two numbers stood out to me. First, 45.3 percent of participants on the top dose hit 30 percent or more weight loss. Thirty percent is the threshold we have historically reached only with bariatric surgery. Second, 65.3 percent dropped below the obesity threshold entirely, meaning their BMI moved from above 30 to below 30. This is the biggest weight loss number we have ever seen from a single injection in a phase 3 obesity study.

Why are the numbers this big

Semaglutide, the active ingredient in Ozempic and Wegovy, is a GLP-1 receptor agonist. It is one receptor, one lever. Retatrutide is a triple agonist. It hits three receptors at the same time: GLP-1, GIP, and glucagon.

Here is what each one does:

•     GLP-1: lowers appetite and improves how your body handles blood sugar.

•     GIP: adds to that effect and improves how your body handles fat.

•     Glucagon: this is the part that is actually new. At the right level, glucagon agonism increases energy expenditure. In plain English, your body burns more calories at rest.

Think of Ozempic as pressing the brake pedal on appetite. Retatrutide presses the brake and gently presses the gas pedal on metabolism at the same time. That combination is why the weight loss is not a marginal improvement. It is a different category. The original phase 2 trial, published in the New England Journal of Medicine in 2023, showed 24.2 percent weight loss at 48 weeks on the 12 mg dose. The phase 3 data confirmed it at a large scale.

The dose response

In TRIUMPH-1, participants were assigned to one of three doses or a placebo. The results scaled cleanly with the dose:

•     4 mg: about 19 percent of body weight, roughly 47 pounds, reached with only a single escalation step.

•     9 mg: about 25.9 percent, roughly 64 pounds.

•     12 mg: about 28.3 percent, roughly 70 pounds.

•     Placebo: about 2 percent, essentially nothing.

The extension data was even more striking. Participants who started with a BMI above 35 and continued on retatrutide for 104 weeks instead of 80 lost an average of 85 pounds. That is 30.3 percent of their starting body weight, with no sign of a plateau.

For comparison, the pivotal STEP 1 trial for semaglutide at 2.4 mg, which is Wegovy's highest dose, showed about 14.9 percent body weight reduction at 68 weeks. Retatrutide is roughly twice that.

What improved beyond the scale

Weight is the headline, but the cardiometabolic markers moved in the right direction across the board. Waist circumference dropped. Triglycerides dropped. Blood pressure dropped. High-sensitivity C-reactive protein, a blood marker for inflammation, also dropped significantly. These are the same risk factors that drive long-term damage to the heart and the kidneys, which is the part I care about most as a nephrologist.

The side effects, and the one that matters most for your kidneys

The classical side effects for this drug family are nausea, vomiting, diarrhea, constipation, and abdominal discomfort. These are dose-dependent. Most are mild to moderate, but they become more common as the dose climbs. There are also signals across the incretin class worth monitoring, including gallbladder events, mild increases in heart rate, and pancreatitis cases.

Here is the part most coverage skips. The side effect that matters most for your kidneys is dehydration. If you have severe nausea or vomiting and you cannot keep fluid down for more than 24 hours, you can spiral into acute kidney injury fast. I see this in my kidney clinic

during GLP-1 dose escalations. This is the conversation you need to have with your prescriber on day one, not after a problem starts.

Ask three questions and write the answers down:

•     When do I hold the drug? Know the threshold before you reach it.

•     When do I call the office? Have a clear trigger for picking up the phone.

•     When do I go to the emergency room? This is the one you least want to improvise.

The plan needs to exist before you need it, not during.

GLP-1s and kidney protection: the honest answer

If you have kidney disease, you have probably heard that GLP-1s protect the kidneys. Here is the honest version. Semaglutide has actual kidney outcomes data. Retatrutide does not have it yet.

In the FLOW trial, published in the New England Journal of Medicine in 2024, semaglutide reduced major kidney events by 24 percent in adults with type 2 diabetes and chronic kidney disease. All-cause mortality dropped 20 percent, and major cardiovascular events dropped 18 percent. That is a finished, peer-reviewed phase 3 study. Retatrutide does not have that yet. The cardiovascular outcomes trial is ongoing, and kidney outcomes were not the primary endpoint of TRIUMPH-1.

That said, the drivers of kidney damage in metabolic disease are obesity, insulin resistance, high blood pressure, and inflammation. Retatrutide drops weight, improves blood pressure, lowers triglycerides, and reduces C-reactive protein. All four moving in the right direction should be kidney favorable. But should be is not the same as is, and we need the study.

Think of it like a car with better dashboard readings. Fuel economy is up, engine temperature is down, and emissions are cleaner. You expect the car to last longer, but you do not say it lasts longer until somebody has put 200,000 miles on it.

When can you actually get it?

Realistically, sometime in early 2027. Two more phase 3 readouts still have to come in: TRIUMPH-2 in patients with type 2 diabetes, and TRIUMPH-3 in patients with established cardiovascular disease. Eli Lilly will file for FDA approval once the pivotal data are complete, and the FDA review takes its own time. Early 2027 is the realistic window, give or take a quarter.

Do not buy the compounded version online

In the meantime, there are online sellers and some non-regulated clinics advertising retatrutide. My advice is simple. Do not buy it.

Those products are research-grade peptides sourced outside the regulated supply chain. Potency can vary, purity can vary, and safety has never been tested in the formulation showing up at your door. It is the same word on the label, but a completely different product. Imagine ordering a clinical-grade medication from the trial pharmacy, and what arrives is a powder mixed in a basement by someone you have never met. The trial drug went through quality control at pharmaceutical manufacturing standards. The compounded peptides have not. There is a reason these are not FDA-approved yet.

Three things to do this week

This next part is what most of my patients tell me they wish they had heard before they started any obesity drug. Here is what to do.

•     1. Watch your hydration during any dose escalation. If you are on a GLP-1 now, the single most common cause of acute kidney injury on these drugs is dehydration from GI side effects. If you cannot keep your fluids down for more than 24 hours, call your doctor the same day.

•     2. If you are waiting on retatrutide, wait. Compounded versions are not the trial drug. The real one is coming, probably early 2027, through a regulated supply, and in my opinion it is worth the wait. In the meantime you have options like Ozempic, Wegovy, Zepbound, and Mounjaro.

•     3. Defend your muscle. Bigger weight loss also means bigger absolute muscle loss. Aim for two to three resistance training sessions a week. Bands, machines, body weight, or dumbbells all count. Pair that with high-quality protein at a level appropriate for your kidney stage. If you have chronic kidney disease, that protein number is a question for your nephrologist, not Google.

And a clear red flag: if you are on any obesity medication and your urine output drops sharply, you are severely nauseated, or your blood pressure is swinging, that is a call to your prescriber the same day. It is not a wait-and-see.

The bottom line

Retatrutide is the most powerful weight loss injection we have seen in a phase 3 obesity trial, and the early signals on the markers that drive kidney and heart disease look encouraging. The catch is that the outcomes data is not in yet, and the version worth taking is the regulated one that is still a year or so away. If you are on a GLP-1 today, the most useful thing you can do is protect your hydration and your muscle, and build your safety plan with your prescriber before you need it.

Disclaimer

This article is for general educational purposes and reflects published trial data as of June 2026. It is not medical advice and does not replace a conversation with your own physician. Retatrutide is investigational and not FDA-approved. Medication decisions, including starting, stopping, or dosing any GLP-1 or related drug, should be made with your prescriber based on your individual health.